Make Informed Investment Decisions with Affordable Access to Experts
Discussion of IDO inhibitors from a basic science and research perspective. Specifically discussing potential bioavailability and solubility issues.Ticker(s): NLNK, BMY, RHHBY
NIH research scientist that has the ability to speak to the bioavailability and solubility characteristics of the IDO1 class.
Please explain your background working with IDO inhibitors.Added By: joemac84
What are you impressions of IDO inhibitors currently under development as a pathway and class of therapies?Added By: joemac84
Can you explain how indoximod (wholly owned by Nlnk, data read out at asco June 2016) which has a different MOA than 919 or incy's ido, works? Do you feel that it has a compelling profile?Added By: lichaim18
1. Can you compare the profiles of epacodostst to gdc-0919? I believe their pk profiles are both publicly characterized. Do you see any differences?
2. Do you think Roche / Genentech will take gdc-0919 forward in late stage trials, as Merck /incyte did with EPA?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.